Elevidys sales weaken; Neumora gets into obesity
Written by
BioPharma Dive
Published
0
comments
0
min
Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.